Analyst upgrades typically lead to a positive short-term reaction in the stock market as they suggest improved fundamentals or future prospects for the company. The substantial raise in the price target from $52 to $85 by B of A Securities reflects a strong conviction in Apellis Pharmaceuticals' potential for growth and profitability, which is likely to be viewed favorably by investors.